Megyesfalvi Z, Gay CM, Popper H, Pirker R, Ostoros G, Heeke S, Lang C, Hoetzenecker K, Schwendenwein A, Boettiger K, et al. Clinical insights into small cell lung cancer: tumor heterogeneity, diagnosis, therapy, and future directions. CA Cancer J Clin. 2023;73(6):620–52.

Article  PubMed  Google Scholar 

Goldberg SB, Contessa JN, Omay SB, Chiang V. Lung cancer brain metastases. Cancer J. 2015;21(5):398–403.

Article  PubMed  Google Scholar 

Ganti AKP, Loo BW, Bassetti M, Blakely C, Chiang A, D’Amico TA, D’Avella C, Dowlati A, Downey RJ, Edelman M, et al. Small cell lung cancer, version 22022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(12):1441–64.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Farago AF, Keane FK. Current standards for clinical management of small cell lung cancer. Transl Lung Cancer Res. 2018;7(1):69–79.

Article  PubMed  PubMed Central  Google Scholar 

Pommier Y, Leo E, Zhang H, Marchand C. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol. 2010;17(5):421–33.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Owonikoko TK, Behera M, Chen Z, Bhimani C, Curran WJ, Khuri FR, Ramalingam SS. A systematic analysis of efficacy of second-line chemotherapy in sensitive and refractory small-cell lung cancer. J Thorac Oncol. 2012;7(5):866–72.

Article  PubMed  PubMed Central  Google Scholar 

von Pawel J, Jotte R, Spigel DR, O’Brien ME, Socinski MA, Mezger J, Steins M, Bosquée L, Bubis J, Nackaerts K, et al. Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. J Clin Oncol. 2014;32(35):4012–9.

Article  Google Scholar 

Pal Choudhuri S, Girard L, Lim JYS, Wise JF, Freitas B, Yang D, Wong E, Hamilton S, Chien VD, Kim YJ, et al. Acquired cross-resistance in small cell lung cancer due to extrachromosomal DNA amplification of MYC paralogs. Cancer Discov. 2024;14(5):804–27.

Article  PubMed  PubMed Central  Google Scholar 

Sun Y, Shen W, Hu S, Lyu Q, Wang Q, Wei T, Zhu W, Zhang J. METTL3 promotes chemoresistance in small cell lung cancer by inducing mitophagy. J Exp Clin Cancer Res. 2023;42(1):65.

Article  PubMed  PubMed Central  Google Scholar 

Ying Q, Fan R, Shen Y, Chen B, Zhang J, Li Q, Shi X. Small cell lung cancer-an update on chemotherapy resistance. Curr Treat Options Oncol. 2024;25(8):1112–23.

Article  PubMed  Google Scholar 

Lawson MH, Cummings NM, Rassl DM, Russell R, Brenton JD, Rintoul RC, Murphy G. Two novel determinants of etoposide resistance in small cell lung cancer. Cancer Res. 2011;71(14):4877–87.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schenk MW, Humphrey S, Hossain A, Revill M, Pearsall S, Lallo A, Brown S, Bratt S, Galvin M, Descamps T, et al. Soluble guanylate cyclase signalling mediates etoposide resistance in progressing small cell lung cancer. Nat Commun. 2021;12(1):6652.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Omori M, Noro R, Seike M, Matsuda K, Hirao M, Fukuizumi A, Takano N, Miyanaga A, Gemma A. Inhibitors of ABCB1 and ABCG2 overcame resistance to topoisomerase inhibitors in small cell lung cancer. Thorac Cancer. 2022;13(15):2142–51.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hansen LT, Lundin C, Spang-Thomsen M, Petersen LN, Helleday T. The role of RAD51 in etoposide (VP16) resistance in small cell lung cancer. Int J Cancer. 2003;105(4):472–9.

Article  CAS  PubMed  Google Scholar 

Zhang SR, Pan M, Gao YB, Fan RY, Bin XN, Qian ST, Tang CL, Ying HJ, Wu JQ, He MF. Efficacy and mechanism study of cordycepin against brain metastases of small cell lung cancer based on zebrafish. Phytomedicine. 2023;109: 154613.

Article  CAS  PubMed  Google Scholar 

Fan RY, Wu JQ, Liu YY, Liu XY, Qian ST, Li CY, Wei P, Song Z, He MF. Zebrafish xenograft model for studying mechanism and treatment of non-small cell lung cancer brain metastasis. J Exp Clin Cancer Res. 2021;40(1):371.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vilariño N, Bruna J, Bosch-Barrera J, Valiente M, Nadal E. Immunotherapy in NSCLC patients with brain metastases: Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic. Cancer Treat Rev. 2020;89:102067.

Article  PubMed  Google Scholar 

Hodkinson PS, Mackinnon AC, Sethi T. Extracellular matrix regulation of drug resistance in small-cell lung cancer. Int J Radiat Biol. 2007;83(11–12):733–41.

Article  CAS  PubMed  Google Scholar 

Zhang Y, Wang L, Zi Y, Zhang L, Guo Y, Huang Y. Oridonin effectively reverses the drug resistance of cisplatin involving induction of cell apoptosis and inhibition of MMP expression in human acute myeloid leukemia cells. Saudi J Biol Sci. 2017;24(3):678–86.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang X, Li X, Dai X, Zhang X, Zhang J, Xu T, Lan Q. Coaxial extrusion bioprinted shell-core hydrogel microfibers mimic glioma microenvironment and enhance the drug resistance of cancer cells. Colloids Surf B Biointerfaces. 2018;171:291–9.

Article  CAS  PubMed  Google Scholar 

Mark C, Warrick J, Callander NS, Hematti P, Miyamoto S. A hyaluronan and proteoglycan link protein 1 matrikine: role of matrix metalloproteinase 2 in multiple myeloma NF-κB activation and drug resistance. Mol Cancer Res. 2022;20(9):1456–66.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li H, Xu X, Liu Y, Li S, Zhang D, Meng X, Lu L, Li Y. MMP7 induces T-DM1 resistance and leads to the poor prognosis of gastric adenocarcinoma via a DKK1-dependent manner. Anticancer Agents Med Chem. 2018;18(14):2010–6.

Article  CAS  PubMed  Google Scholar 

Ohashi S, Natsuizaka M, Nakagawa H. MMP7 and activation of IGF-1R: a new insight into anti-EGFR therapeutic resistance in metastatic colorectal cancer. Cancer Biol Ther. 2011;11(2):184–7.

Article  CAS  PubMed  Google Scholar 

Liu Z, Lai J, Jiang H, Ma C, Huang H. Collagen XI alpha 1 chain, a potential therapeutic target for cancer. Faseb j. 2021;35(6): e21603.

Article  CAS  PubMed  Google Scholar 

Reinhard J, Wagner N, Krämer MM, Jarocki M, Joachim SC, Dick HB, Faissner A, Kakkassery V. Expression Changes and impact of the extracellular matrix on etoposide resistant human retinoblastoma cell lines. Int J Mol Sci. 2020;21(12):4322.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fujita Y, Kitagawa M, Nakamura S, Azuma K, Ishii G, Higashi M, Kishi H, Hiwasa T, Koda K, Nakajima N, et al. CD44 signaling through focal adhesion kinase and its anti-apoptotic effect. FEBS Lett. 2002;528(1–3):101–8.

Article  CAS  PubMed  Google Scholar 

Jin H, He Y, Zhao P, Hu Y, Tao J, Chen J, Huang Y. Targeting lipid metabolism to overcome EMT-associated drug resistance via integrin β3/FAK pathway and tumor-associated macrophage repolarization using legumain-activatable delivery. Theranostics. 2019;9(1):265–78.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Luo J, Yao JF, Deng XF, Zheng XD, Jia M, Wang YQ, Huang Y, Zhu JH. 14, 15-EET induces breast cancer cell EMT and cisplatin resistance by up-regulating integrin αvβ3 and activating FAK/PI3K/AKT signaling. J Exp Clin Cancer Res. 2018;37(1):23.

Article  PubMed  PubMed Central  Google Scholar 

Uchihara T, Miyake K, Yonemura A, Komohara Y, Itoyama R, Koiwa M, Yasuda T, Arima K, Harada K, Eto K, et al. Extracellular vesicles from cancer-associated fibroblasts containing annexin A6 induces FAK-YAP activation by stabilizing β1 integrin enhancing drug resistance. Cancer Res. 2020;80(16):3222–35.

Article